LAKE FOREST, Calif.--(BW HealthWire)--July 15, 2002--Daniel G. Mc Guire, president and CEO of Worldwide Medical Corporation (OTCBB:WMED) (www.wwmed.com), the exclusive marketer of First Check(R) branded home screening tests for drugs of abuse, alcohol, cholesterol, and colorectal disease announces today that the company has secured a significant distribution agreement with Natures Bounty (NBTY), the nations largest American-owned, premier manufacture of healthcare products. First Check's home cholesterol tests, along with our colorectal home screening test are now available to over 6,000,000 new health conscious consumers utilizing two of America's leading healthcare direct mail catalogs, Puritan Pride and L&H Vitamins.
NBTY is a leading vertically integrated manufacture, wholesaler, and marketer of high quality, value-priced nutrition and healthcare products operating in the United States, United Kingdom, and worldwide. NBTY operates over 500 wholesale stores in the US and over 420 in the UK. More importantly NBTY's mail order catalogs regularly reach over 6,000,000 health conscious targeted consumers.
Worldwide Medical President and CEO, Daniel G. Mc Guire stated, "The Company is very enthusiastic and plans to leverage the unique opportunity that NBTY provides. Our First Check home screening tests are now available to millions of new consumers via NBTY's integrated wholesale mail order distribution network. Our research indicates that over 25% of consumers that would be interested in purchasing our First Check home tests would prefer to do so utilizing a confidential mail order process. We remain committed to diversifying the company's channels of distribution beyond traditional brick and mortar drug stores."
Forward - looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward looking statements involve risk and uncertainties, including, but not limited to, the results of research and development efforts, the effect of the United States Food and Drug Administration and other agencies, the impact of competitive products, access to capital, market demand for the company's products, changes in trade practices and the risk of trade practice litigation, technological changes, intellectual property rights, and other risks detailed from time to time in the company's reports.